Search clinical trials for: BI 764532, formulation 1

Total 348 results

Boehringer Ingelheim

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Small Cell Lung Carcinoma | Neuroendocrine Neoplasms

United States, Belgium, Spain, Korea, Republic of, United Kingdom, Germany, Japan, China, Taiwan, France, Portugal, Bulgaria
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Patients With Small Cell Lung Carcinoma and Other Neoplasms

United States, Spain, Germany, Japan
Boehringer Ingelheim

Recruiting

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Netherlands
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Germany, Belgium, Japan, France
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

Glioma

United States, Switzerland, Germany
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body

Healthy

United Kingdom
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 685509 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Recruiting

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Solid Tumors

Hungary
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food

Healthy

Germany
Boehringer Ingelheim

Not yet recruiting

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men

Healthy
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1810631 is Taken up and Processed by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia (HORNBILL)

Diabetic Retinopathy

United States, United Kingdom
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 765423 Are Taken up in the Body of Healthy Men

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study in Healthy Men to Find Out How Well Different Doses of BI 764122 Are Tolerated and Whether Food Affects the Amount of BI 764122 in the Blood

Healthy

Belgium
Boehringer Ingelheim

Completed

Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food

Healthy

Germany
Boehringer Ingelheim

Terminated

A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

Macular Degeneration

United Kingdom, United States
AstraZeneca

Completed

To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers

Parkinson's Disease

United Kingdom
Pfizer

Completed

Single Dose Study To Compare Pharmacokinietics Of 3 Different Formulations Of PF-04991532 In Healthy Volunteers

Healthy

Singapore
Midwest Center for Metabolic and Cardiovascular...
Pharmavite LLC

Completed

Bioavailability of Select Nutrients From Two Formulations of a Multivitamin/Mineral Supplement

Bioavailability

United States
Boehringer Ingelheim

Recruiting

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan

Small Cell Lung Carcinoma (SCLC)

United Kingdom, Germany, Poland
LEO Pharma

Completed

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

Actinic Keratosis

Canada, United States
GlaxoSmithKline

Active, not recruiting

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

Herpes Simplex

Germany, United States, Belgium, Canada, Spain, United Kingdom, Estonia, Australia
Boehringer Ingelheim

Recruiting

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States, Korea, Republic of, Israel, Spain, Australia, Japan, Italy, Germany, Denmark, Belgium, Lithuania, China, Canada, Malaysia, Singapore, New Zealand, France, Mexico, Netherlands, Greece, United Kingdom, Bulgaria, Philipp... and more
Eli Lilly and Company

Completed

A Study to Compare Two Formulations of LY3209590 in Healthy Participants

Healthy

Singapore
Vifor (International) Inc.

Completed

Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects

Healthy

United Kingdom
Boehringer Ingelheim

Completed

A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

Healthy

Germany
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

HIV Infections | Infection, Human Immunodeficiency Virus

United States
HK inno.N Corporation

Completed

A Study to Compare the Pharmacokinetic Characteristics of CJ-12420

Erosive Esophagitis

Korea, Republic of
Boehringer Ingelheim

Recruiting

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Neuroendocrine Neoplasms

Spain, Germany, Japan
Boehringer Ingelheim

Not yet recruiting

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Diabetic Retinopathy
Boehringer Ingelheim

Completed

Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers

Healthy

Germany
Imperial Brands PLC
Nerudia Ltd

Completed

An Exploratory PET-study of Deposition, Disposition and Brain Uptake of [11C]Nicotine After Inhalation of 2 Nicotine Formulations Via the myBluTM E-cigarette in Smokers

Healthy Volunteers

Sweden
Chong Kun Dang Pharmaceutical

Completed

Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-828 in Healthy Subjects

Hypertension

Korea, Republic of
Atea Pharmaceuticals, Inc.
Hoffmann-La Roche

Completed

Study of AT-527 in Healthy Subjects (R07496998)

Healthy Volunteer Study

Canada
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants

Healthy

Belgium
Boehringer Ingelheim

Completed

Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

Lupus Nephritis

Spain, United Kingdom, United States, Canada, Thailand, Germany, Italy, Japan, Serbia, Australia, Korea, Republic of, Mexico, Malaysia, Philippines, Poland, Portugal, Greece, Hong Kong, Czechia, France
GlaxoSmithKline

Completed

A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 Years (TH HSV REC-004)

Herpes Simplex

Japan
Allergan

Completed

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

Androgenetic Alopecia

United States
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers

Healthy

Korea, Republic of
Sanofi Pasteur, a Sanofi Company
Immune Design

Terminated

Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2 (HSV15)

Genital Herpes

United States
Boehringer Ingelheim

Completed

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

Schizophrenia

Spain, Korea, Republic of, United Kingdom, Taiwan, United States, Austria, Italy, Germany, Poland, Japan, Canada
National Research Council, Spain
Hospital Universitario Reina Sofia de Cordoba

Completed

Pomegranate Extract Supplementation in Colorectal Cancer Patients (POMEcolon)

Colorectal Cancer

Spain
Boehringer Ingelheim

Completed

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Alzheimer Disease

Spain, United Kingdom, Italy, United States, Canada, Germany, Greece, Austria, Norway, France, Japan, Hungary, Poland, Finland
Aragon Pharmaceuticals, Inc.

Completed

Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants

Healthy

United States
Pendulum Therapeutics

Terminated

Placebo-Controlled Clinical Nutrition Study of the Metabolic Effects of Food Product WBF-0011 in Type 2 Diabetes

Type 2 Diabetes Mellitus

Ireland
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

Infection, Human Immunodeficiency Virus | Infections, Human Immunodeficiency Virus and Herpesviridae

United States
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers

Hypertension | Dyslipidemias

Korea, Republic of
Boehringer Ingelheim

Completed

A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood

Healthy

Germany
Baylor College of Medicine

Completed

Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults

Hookworm Infection | Hookworm Disease

Brazil

3

Subscribe